Helping You Build Wealth With Honest Research
Since 1996. Read On...

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Panacea Biotech Gains 8%; BSE HEALTHCARE Index Up 1.2%
Thu, 4 Jul 16:42

Panacea Biotech Gains 8%; BSE HEALTHCARE Index Up 1.2%Image source: phive2015/www.istockphoto.com

Panacea Biotech share price has zoomed 8% and is presently trading at Rs 144.0.

Meanwhile, the BSE HEALTHCARE index is at 37,866.5 (up 1.2%).

Among the top gainers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (up 11.9%) and Lupin (up 8.2%).

ERIS LIFESCIENCES (down 1.5%) and SUVEN PHARMACEUTICALS (down 1.2%) are among the top losers today.

Over the last one year, Panacea Biotech has moved up from Rs 126.0 to Rs 144.0, registering a gain of Rs 18.0 (up 14.3%).

On the other hand, the BSE HEALTHCARE index has moved up from 25,627.6 to 37,866.5, registering a gain of 47.8% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were Lupin (up 97.7%), Cadila Healthcare (up 97.1%) and Glenmark Pharma (up 96.8%).

Must See: These Segments are Witnessing Incredible Growth with Modi's Push

What About the Benchmark Indices?

The BSE Sensex is at 80,049.7 (up 0.1%).

The top gainers among the BSE Sensex today are Tata Motors (up 2.7%) and HCl Tech. (up 2.7%). The most traded stocks in the BSE Sensex are Tata Motors and Tata Steel.

In the meantime, NSE Nifty is at 24,304.7 (up 0.1%). Tata Motors and HCl Tech. are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved up from 65,205.1 to 80,049.7, registering a gain of 14,844.6 points (up 22.8%).

Panacea Biotech Financial Update...

Panacea Biotech net profit grew 84.3% YoY to Rs -20 million for the quarter ended March 2024, compared to a loss of Rs 127 million a year ago. Net sales rose 5.8% to Rs 1,365 million during the period as against Rs 1,289 million in January-March 2023.

For the year ended March 2023, Panacea Biotech reported 103.1% decrease in net profit to Rs -337 million compared to net profit of Rs 10,783 million during FY22. Revenue of the company fell 30.4% to Rs 4,599 million during FY23.

The current Price to earnings ratio of Panacea Biotech, based on rolling 12 month earnings, stands at -588.2.


Equitymaster requests your view! Post a comment on "Panacea Biotech Gains 8%; BSE HEALTHCARE Index Up 1.2%". Click here!